FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216786237> ?p ?o ?g. }

• W3216786237 endingPage "1974" @default.
• W3216786237 startingPage "1974" @default.
• W3216786237 abstract "Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1." @default.
• W3216786237 created "2021-12-06" @default.
• W3216786237 creator A5002404985 @default.
• W3216786237 creator A5014071440 @default.
• W3216786237 creator A5016617825 @default.
• W3216786237 creator A5029710444 @default.
• W3216786237 creator A5037492526 @default.
• W3216786237 creator A5044027343 @default.
• W3216786237 creator A5048651688 @default.
• W3216786237 creator A5074669391 @default.
• W3216786237 creator A5074744219 @default.
• W3216786237 creator A5082629419 @default.
• W3216786237 creator A5090698986 @default.
• W3216786237 date "2021-11-21" @default.
• W3216786237 modified "2023-10-16" @default.
• W3216786237 title "The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy" @default.
• W3216786237 cites W166486881 @default.
• W3216786237 cites W1966000502 @default.
• W3216786237 cites W1966658428 @default.
• W3216786237 cites W1975917154 @default.
• W3216786237 cites W1985312565 @default.
• W3216786237 cites W2008883059 @default.
• W3216786237 cites W2020558940 @default.
• W3216786237 cites W2036854621 @default.
• W3216786237 cites W2037248548 @default.
• W3216786237 cites W2046276878 @default.
• W3216786237 cites W2068934207 @default.
• W3216786237 cites W2076131513 @default.
• W3216786237 cites W2087865968 @default.
• W3216786237 cites W2093855538 @default.
• W3216786237 cites W2105177613 @default.
• W3216786237 cites W2112512464 @default.
• W3216786237 cites W2121131635 @default.
• W3216786237 cites W2123552223 @default.
• W3216786237 cites W2131312664 @default.
• W3216786237 cites W2134450909 @default.
• W3216786237 cites W2151856262 @default.
• W3216786237 cites W2153565541 @default.
• W3216786237 cites W2159330187 @default.
• W3216786237 cites W2166199281 @default.
• W3216786237 cites W2171070913 @default.
• W3216786237 cites W2285875128 @default.
• W3216786237 cites W2318605753 @default.
• W3216786237 cites W2605265954 @default.
• W3216786237 cites W2791476909 @default.
• W3216786237 cites W2889410466 @default.
• W3216786237 cites W2912756192 @default.
• W3216786237 cites W2967084136 @default.
• W3216786237 cites W3050283202 @default.
• W3216786237 cites W3116101462 @default.
• W3216786237 cites W3136586072 @default.
• W3216786237 cites W3159774835 @default.
• W3216786237 cites W3189242018 @default.
• W3216786237 cites W4243575509 @default.
• W3216786237 doi "https://doi.org/10.3390/pharmaceutics13111974" @default.
• W3216786237 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8617914" @default.
• W3216786237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34834389" @default.
• W3216786237 hasPublicationYear "2021" @default.
• W3216786237 type Work @default.
• W3216786237 sameAs 3216786237 @default.
• W3216786237 citedByCount "4" @default.
• W3216786237 countsByYear W32167862372022 @default.
• W3216786237 crossrefType "journal-article" @default.
• W3216786237 hasAuthorship W3216786237A5002404985 @default.
• W3216786237 hasAuthorship W3216786237A5014071440 @default.
• W3216786237 hasAuthorship W3216786237A5016617825 @default.
• W3216786237 hasAuthorship W3216786237A5029710444 @default.
• W3216786237 hasAuthorship W3216786237A5037492526 @default.
• W3216786237 hasAuthorship W3216786237A5044027343 @default.
• W3216786237 hasAuthorship W3216786237A5048651688 @default.
• W3216786237 hasAuthorship W3216786237A5074669391 @default.
• W3216786237 hasAuthorship W3216786237A5074744219 @default.
• W3216786237 hasAuthorship W3216786237A5082629419 @default.
• W3216786237 hasAuthorship W3216786237A5090698986 @default.
• W3216786237 hasBestOaLocation W32167862371 @default.
• W3216786237 hasConcept C121608353 @default.
• W3216786237 hasConcept C126322002 @default.
• W3216786237 hasConcept C134306372 @default.
• W3216786237 hasConcept C150903083 @default.
• W3216786237 hasConcept C153911025 @default.
• W3216786237 hasConcept C185592680 @default.
• W3216786237 hasConcept C197336794 @default.
• W3216786237 hasConcept C202751555 @default.
• W3216786237 hasConcept C207001950 @default.
• W3216786237 hasConcept C2777807558 @default.
• W3216786237 hasConcept C2781230642 @default.
• W3216786237 hasConcept C33923547 @default.
• W3216786237 hasConcept C502942594 @default.
• W3216786237 hasConcept C55493867 @default.
• W3216786237 hasConcept C71924100 @default.
• W3216786237 hasConcept C86803240 @default.
• W3216786237 hasConcept C98274493 @default.
• W3216786237 hasConceptScore W3216786237C121608353 @default.
• W3216786237 hasConceptScore W3216786237C126322002 @default.
• W3216786237 hasConceptScore W3216786237C134306372 @default.
• W3216786237 hasConceptScore W3216786237C150903083 @default.
• W3216786237 hasConceptScore W3216786237C153911025 @default.
• W3216786237 hasConceptScore W3216786237C185592680 @default.

• next